Literature DB >> 22529407

Should All High-Risk Patients Receive Acetylsalicylic Acid 81 mg Daily for Primary Prevention of Cardiovascular Disease?

.   

Abstract

Entities:  

Year:  2012        PMID： 22529407      PMCID： PMC3329907          DOI： 10.4212/cjhp.v65i2.1122

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  11 in total

1.  A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use.

Authors:  Angel Lanas; Maria Angeles Perez-Aisa; Faust Feu; Julio Ponce; Esteban Saperas; Santos Santolaria; Luis Rodrigo; Joaquim Balanzo; Eduardo Bajador; Pedro Almela; Jose M Navarro; Fernando Carballo; Manuel Castro; Enrique Quintero
Journal:  Am J Gastroenterol       Date:  2005-08       Impact factor: 10.864

2.  The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines.

Authors:  Alan D Bell; André Roussin; Raymond Cartier; Wee Shian Chan; James D Douketis; Anil Gupta; Maria E Kraw; Thomas F Lindsay; Michael P Love; Neesh Pannu; Rémi Rabasa-Lhoret; Ashfaq Shuaib; Philip Teal; Pierre Théroux; Alexander G G Turpie; Robert C Welsh; Jean-François Tanguay
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

3.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.

Authors:  G de Gaetano
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

4.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors: 
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

5.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

6.  Final report on the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

7.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

8.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

9.  Randomised trial of prophylactic daily aspirin in British male doctors.

Authors:  R Peto; R Gray; R Collins; K Wheatley; C Hennekens; K Jamrozik; C Warlow; B Hafner; E Thompson; S Norton
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-30

10.  Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications.

Authors:  Sonia Hernández-Díaz; Luis A García Rodríguez
Journal:  BMC Med       Date:  2006-09-20       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.